胸腺肽α1对COPD患者细胞免疫功能影响.docVIP

胸腺肽α1对COPD患者细胞免疫功能影响[摘要] 目的 研究胸腺肽α1对COPD患者细胞免疫功能的影响。方法 60例COPD患者分为对照组与治疗组各30例。对照组进行常规治疗，治疗组于常规治疗外加用胸腺肽α1，每周2次，共4周。结果 治疗组通过胸腺肽α1治疗后，CD4+及CD4+/CD8+均明显升高，CD8+明显下降，治疗前后比较差异均有统计学意义（P＜0.01）；治疗组PaO2、FEV1%治疗后均明显升高，PaCO2治疗后明显降低，与对照组治疗后比较差异均有统计学意义（P＜0.01）。结论 胸腺肽能够增强慢性阻塞性肺疾病的细胞免疫能力，能降低其急性发作频率。 [关键词] 慢性阻塞性肺疾病；胸腺肽；细胞免疫力 [中图分类号] R563 [文献标识码] B [文章编号] 1673-9701（2011）19-86-02 Effect of Thymosinα1 on Cell Immune Functions in COPD Patients WENG Weiwen Guangdong Province Lianzhou People’s Hospital，Lianzhou 513400，China [Abstract] Objective To study the effect of thymosin α1 on cellular immune function of COPD patients. Methods 60 cases of COPD patients were divided into control group and treatment group，30 patients in each group. Control group received conventional treatment；Patients in the treatment group were treated with conventional treatment plus thymosinα1，2 times per week for 4 weeks. Results In treatment group after treatment by thymosinα1，CD4+，and CD4+/CD8+ increased and CD8+ decreased，there were statistical differences between before and after treatment（P＜0.01）；PaO2 and FEV1% increased significantly，PaCO2 decreased significantly after treatment，there were statistical differences between treatment group and control group after treatment（P＜0.01）. Conclusion Thymosin enhances chronic obstructive pulmonary disease cell immunity and can reduce the frequency of acute attacks. [Key words] Chronic obstructive pulmonary disease；Thymosin；Cellular immunity 以气流受阻呈现不可逆进行性发展特征的慢性阻塞性肺病（COPD）疾病，其对气体及有害颗粒呈现过度的炎症症状，并且常伴随全身系统性的炎症症状[1]，因具有患病人数多、死亡率高的特点，被社会所关注[2]。COPD分为急性加重期与稳定期，急性加重期常常伴随长时间的病程，给患者身心带来极大伤害，而胸腺肽作为对其免疫力与急性发作有影响的药物，正为广大的医疗工作者所关注。 1 资料与方法 1.1一般资料 入选60例COPD急性加重期患者，均符合慢性阻塞性肺疾病全球创议（GOLD）诊断标准，即应用支气管舒张剂后患者FEV1/FVC＜70%，排除对胸腺肽α1有过敏史、有严重肝肾功能损害者、病情危重或有严重并发症影响治疗效果者。按随机数字表法分为两组：治疗组30例，男19例，女11例，平均年龄（62.6±7.8）岁；对照组30例，男16例，女14例，平均年龄（60.3±8.8）岁。两组患者的性别、年龄差异均无统计学意义（P＞0.05）。 1.2治疗方法 两组均进行常规的抗感染（应用3代头孢菌素，同时进行痰培养+药敏，后根据药敏应用抗生素）。治疗组同时应用胸腺肽α1治疗，每周2次，共4周；后分别检测其外周血